COL19A1 and amyotrophic lateral sclerosis: The findings in this study revealed that COL19A1 levels in muscle biopsies and blood samples from ALS patients can be considered a prognostic biomarker to accurately monitor the disease progression, especially in those patients that share a high disability in the first symptomatic stages of the disease.